Feedback / Questions
sabirnetug IV (ACU193 IV) - Acumen Pharma
https://www.globenewswire.com/news-release/2024/03/08/2843122/0/en/Acumen-Pharmaceuticals-Presents-Sabirnetug-ACU193-Fluid-Biomarker-and-Target-Engagement-Analyses-from-Phase-1-INTERCEPT-AD-Study-in-Early-Alzheimer-s-at-the-AD-PD-2024-Annual-Meeti.html
Mar 8, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next